Researchers have demonstrably improved the course of the novel solution for cardiac amyloidosis, employing the investigational drug. Preliminary patient results reveals potential outcomes for those diagnosed from the serious illness. This emphasis represents BridgeBio's commitment to managing unmet medical needs in this heart disease arena. Attrub